Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety study of Recaticimab in ASCVD or high-risk ASCVD patients not meeting lipid targets
ChiCTR2500099939Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of recaticimab in atherosclerotic disease and hyperlipidemia (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Blood lipids at week 96. Started Apr 2025; status: recruiting.
02
Drugs
recaticimab
03
Conditions
atherosclerotic diseasehyperlipidemia
Beyond the preview
Go deeper on ChiCTR2500099939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099939.